Seeking Therapeutic Interventions and Vaccine Innovations for Hepatitis B and Hepatitis D Viruses

A global pharmaceutical company with cutting-edge capabilities in drug development and a history of successful academic collaborations wishes to identify infectious disease therapeutics and vaccines in European institutes, targeting Hepatitis B and Hepatitis D virus infection.

Further information 

Our client wishes to identify technologies, research projects and spin‑out companies at any stage of development, from basic research to Phase I, focusing on the treatment of Hepatitis B and/or Hepatitis D. Vaccines, novel therapeutics and selective targeting of factors capable of suppressing viral replication are of specific interest.

Research interests

Priority will be given to submissions aligned with one or more of our client’s search criteria below:

• Therapeutic HBV and HDV vaccines
• Immunomodulatory therapeutics to induce sustained disease remission
• Covalently closed circular DNA (cccDNA) inhibitors or destabilizers
• HB S antigen secretion inhibitors targeting either viral or cellular factors
• Technologies targeting capsid assembly, such as capsid assembly modulators (CAMs) or core protein allosteric modulators (CpAMs)
• Agonists of Toll-like receptor 8 (TLR8), retinoic acid-inducible gene I (RIG-I) or stimulator of interferon genes (STING)

Jurisdictions of Interest

Only submissions from institutions in Europe, Africa and the Middle East will be considered.

Submission Information

Submission of one-page technology briefs and information on applicable pre- or post-spinout companies is encouraged. The submission form can be downloaded here.